Results 1 to 10 of about 63,990 (294)

The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force [PDF]

European Psychiatry
The European Clozapine Task Force is a group of psychiatrists and pharmacologists practicing in 18 countries under European Medicines Agency (EMA) regulation, who are deeply concerned about the underuse of clozapine in European countries.
Hélène Verdoux, Robert A. Bittner, Alkomiet Hasan, Mishal Qubad, Elias Wagner, Alexis Lepetit, Manuel Arrojo-Romero, Christian Bachmann, Marieke Beex-Oosterhuis, Jan Bogers, Andreja Celofiga, Dan Cohen, Domenico de Berardis, Marc de Hert, Carlos de Las Cuevas, Bjørn H. Ebdrup, Konstantinos N. Fountoulakis, Daniel Guinart, Dolores Keating, Miloslav Kopeček, John Lally, Judit Lazáry, Jurjen J. Luykx, Olalla Maronas Amigo, Espen Molden, Jimmi Nielsen, Brian O’Donoghue, Pierre Oswald, Flavian S. Radulescu, Christopher Rohde, Marina Sagud, Emilio J. Sanz, Ivona Šimunović Filipčić, Iris E. Sommer, Heidi Taipale, Jari Tiihonen, Heli Tuppurainen, Selene Veerman, Alina Wilkowska, Edoardo Spina, Peter Schulte   +40 more
doaj   +5 more sources

Predictors of clozapine concentration and psychiatric symptoms in patients with schizophrenia. [PDF]

PLoS ONE
Clozapine has superior efficacy to other antipsychotics, especially in patients with treatment-resistant schizophrenia. However, its pharmacokinetics and pharmacodynamics vary largely among patients.
Sang-In Park, Seoyoung Kim, Kwanwoo Park, Uijeong Yu, Yunjeong Jang, Bo-Hyung Kim, Ji Hyun Lee, Euitae Kim   +7 more
doaj   +2 more sources

Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations [PDF]

Therapeutic Advances in Psychopharmacology, 2021
Background: Clozapine is the only medication licenced for treating patients with treatment-refractory schizophrenia. However, there are no evidence-based guidelines as to the optimal plasma level of clozapine to aim for, and their association with ...
Amir Krivoy, Eromona Whiskey, Henrietta Webb-Wilson, Dan Joyce, Derek K. Tracy, Fiona Gaughran, James H. MacCabe, Sukhwinder S. Shergill   +7 more
doaj   +2 more sources

Clozapine cessation

European Psychiatry, 2022
Introduction Approximately 30% of individuals diagnosed with schizophrenia suffer from treatment-resistant or refractory schizophrenia. The gold standard for treatment is clozapine.
H. Ktari, A. Ouertani, S. Madouri, A. Aissa, Y. Zgueb, U. Ouali, R. Jomli   +6 more
doaj   +2 more sources

What is the current scope of research assessing patients’ and clinicians’ perspectives on clozapine treatment? A comprehensive scoping review [PDF]

BMJ Open
Objectives Clozapine is continuously underused. The existing systematic reviews addressing barriers to clozapine prescribing primarily focus on clinical staff’s attitudes and perceived barriers to prescribing.
Jimmi Nielsen, Erik Simonsen, Ole Jakob Storebø, Michelle Iris Jakobsen, Stephen F Austin, Julie Perrine Schaug   +5 more
doaj   +2 more sources

Underuse of recommended treatments among people living with treatment-resistant psychosis

Frontiers in Psychiatry, 2022
BackgroundInternational guidelines recommend that individuals with treatment-resistant psychosis must be treated with clozapine. ECT has also been reported to improve symptom profiles.
Julia M. Lappin, Julia M. Lappin, Kimberley Davies, Kimberley Davies, Maryanne O'Donnell, Maryanne O'Donnell, Ishan C. Walpola, Ishan C. Walpola   +7 more
doaj   +1 more source

Elevated clozapine levels in patients with COVID-19 infection

European Psychiatry, 2021
Introduction Clozapine is the most effective antipsychotic for treatment resistant schizophrenia. In patients treated with clozapine, COVID-19 infection may result in complications including an increased risk of pneumonia, clozapine toxicity, and ...
J. Marti Bonany, E. Pérez Sánchez, M. Pérez Carre, M.I. Martínez Casamitjana, J.R. Fortuny Olive, C. Macias Castellví, E. Carrió Diez, F. Lana Moliner, R. Sánchez González   +8 more
doaj   +1 more source

Point-of-care haematological monitoring during treatment with clozapine

Journal of Laboratory Medicine, 2022
Patients treated with clozapine are required to have regular venous blood samples taken to measure white blood cell (WBC) and neutrophil counts to reduce the risk of agranulocytosis.
Atkins Matthew, McGuire Philip, Balgobin Bhirundra, Williams Sophie, Ceesay Fatou, Desouza Neville, Patel Pravinkumar, Taylor David   +7 more
doaj   +1 more source

Clozapine prescription rates in Southeast Europe: A cross-sectional study

Frontiers in Psychiatry, 2023
IntroductionInternational reports indicate that clozapine is under prescribed. Yet, this has not been explored in Southeast European (SEE) countries. This cross-sectional study investigates clozapine prescription rates in a sample of 401 outpatients with
Manuela Russo, Manuela Russo, Dragana Ignjatovic-Ristic, Dan Cohen, Aliriza Arenliu, Stojan Bajraktarov, Alma Dzubur Kulenovic, Lidija Injac Stevovic, Nadja Maric, Antoni Novotni, Nikolina Jovanovic   +10 more
doaj   +1 more source

Clozapine-associated neutropenia following augmentation with sodium valproate

SAGE Open Medical Case Reports, 2021
Clozapine is gold standard for the management of treatment-resistant schizophrenia. It can offer life-changing symptom reduction where other antipsychotics have failed, and for these patients, treatment with clozapine should be maintained, if in any ...
Michelle Iris Jakobsen, H Grønborg, H V Hansen, A Fink-Jensen   +3 more
doaj   +1 more source